

Cover Story
By Matthew Bin Han Ong
Summer of 2020 was supposed to be a brief period of respite between Wave 1 and Wave 2 of COVID-19, but out of sheer stubbornness, for reasons political, or both, SARS-CoV-2 didn't get the message.
In Brief


Clinical Roundup
Drugs & Targets
Trending Stories
- Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Bhattacharya cancels NIH all-hands meeting
- In the Headlines: “There’s no one to stand up for NCI right now.”
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies